• Explore /
  • Poster
  • / Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

Abstract Poster

Authors

null

Theodoros Foukakis

Karolinska Institutet and University Hospital, Stockholm, Sweden

Theodoros Foukakis , Antroula Papakonstantinou , Alexios Matikas , Nils-Olof Bengtsson , Per Malmström , Elham Hedayati , Guenther G. Steger , Michael Untch , Laila Hübbert , Hemming Johansson , Mats Hellstrom , Michael Gnant , Sibylle Loibl , Richard Greil , Volker Moebus , Jonas C. S. Bergh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT00798070

Citation

J Clin Oncol 37, 2019 (suppl; abstr 553)

DOI

10.1200/JCO.2019.37.15_suppl.553

Abstract #

553

Poster Bd #

45

Abstract Disclosures

Similar Posters

First Author: Atara Isaiah Ntekim

First Author: Sherko Kummel

First Author: Alexios Matikas

First Author: Justin Stebbing